Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

New progress in a long-standing debate about the nature of biological cell membranes could be made by considering which ...

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023 congress.

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potential BMX-502 is a bispecific antibody ...

Laura Ipsen is president and CEO of Ellucian, the leading technology solutions provider for more than 2,900 higher education institutions in 50 countries. She has more than 25 years of experience ...

“We predict in 2025 the biggest disrupter to tech in general will be the adoption of AI agents,” wrote Adam Ipsen, lead content strategist at Pluralsight. The LangChain software framework can ...

Therapy is a process that begins with building a healthy therapeutic relationship. I offer my clients warmth,respect,compassion,honesty and humor so they can work to resolve trauma and painful ...

On Tuesday, RBC Capital Markets updated its outlook for shares of Ipsen (EPA:IPN) SA, a biopharmaceutical company, by increasing the price target from EUR 140.00 to EUR 144.00 while maintaining an ...